<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The objective of the work was to study PIK3CA mutations in <z:mp ids='MP_0002169'>wild type</z:mp> KRAS and BRAF <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Clinicopathological data and paraffin-embedded specimens were collected on 73 patients who underwent colorectal resections at General Yag√ºe Hospital in Burgos </plain></SENT>
<SENT sid="2" pm="."><plain>KRAS, BRAF and PIK3CA status were analyzed by real-time PCR in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="3" pm="."><plain>PIK3CA mutations were present in 8.22% of <z:mp ids='MP_0002169'>wild type</z:mp> KRAS and BRAF <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The most frequent mutation is E545K/D in exon 9 which represents 83.3% of <z:hpo ids='HP_0000001'>all</z:hpo> mutations </plain></SENT>
<SENT sid="5" pm="."><plain>By contrast, we did not found any <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> harbouring H1047R mutation in exon 20 </plain></SENT>
<SENT sid="6" pm="."><plain>Among the patients who undergo a curative resection of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, PIK3CA mutation is present in an important percentage of KRAS and BRAF <z:mp ids='MP_0002169'>wild type</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>PIK3CA mutation may be considered as it could be a hypothetic reason to be not responder to anti-EGFR antibodies </plain></SENT>
</text></document>